Delving into the details, we found 40% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we ...

It's been nearly five years since Moderna (NASDAQ: MRNA) emerged as a biotech industry disruptor, with its COVID-19 vaccine ...

Citigroup assumed coverage on shares of Moderna (NASDAQ:MRNA – Free Report) in a research report report published on Thursday ...

Moderna (MRNA) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the ...

Wealthfront Advisers LLC lowered its stake in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 84.4% during the fourth quarter, according to the company in its most recent disclosure with the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Tom Lee managing partner and head of research at Fundstrat Global Advisors appeared on a CNBC interview to talk about how the ...

RBC analysts also cut their price target for the stock to $320 from $440. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. The Competition and ...

Dr. Markus’s responsi Moderna (MRNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest ...